TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05127070

Intervention type: DEVICE
Intervention: Neotree
Description: The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.

Intervention type: DEVICE
Intervention: Neotree
Description: The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
Study: NCT03580291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: This group receive oral MMF of 2.0 g / d.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Mesenchymal stem cells
Description: The group receive placebo of Mesenchymal stem cells.
Study: NCT04519970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
Study: NCT03894085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine treatment for 4 weeks usage:20-80mg Qd
Study: NCT03580291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Mycophenolate Mofetil
Description: The group receive placebo of oral mycophenolate mofetil.
Study: NCT00102687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.
Study: NCT03894085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine treatment for 4 weeks usage:20-80mg Qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine treatment for 4 weeks usage:20-80mg Qd
Study: NCT00102687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation.
Study: NCT03384017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation and Gait Training
Description: TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session.
Study: NCT04890080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
Study: NCT02046668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spironolactone
Description: spironolactone 25mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: spironolactone 25mg daily for 12 weeks
Study: NCT02892903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Routine Measurement of FFR
Description: FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
Study: NCT01449422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dressing
Description: the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
Study: NCT02226731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Belfort-Dildy Balloon
Description: Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Late Belfort-Dildy balloon
Description: Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
Study: NCT01449422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
Study: NCT00648726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime plus erythromycin
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin (Zithromax)
Description: intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
Study: NCT02810184

Intervention type: RADIATION
Intervention: cone-beam computed tomography (CBCT)
Description: additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
Study: NCT02067949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
Study: NCT01304277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Study: NCT02060669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda
Study: NCT03967626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external cooling with the xxxxx device
Description: external cooling with the xxxxx device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: external cooling with the xxxxx device
Description: external cooling with the xxxxx device
Study: NCT00824135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation, Hematopoietic
Description: Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OKT3
Description: Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day intravenous every 12 hours (2 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60mg/m2 intravenous every 12 hours for 2 doses total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenous for 1 dose total

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
Study: NCT00656721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter Valve
Description: Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done.
Study: NCT03551535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored, At-Home Exercise Intervention
Description: Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
Study: NCT02514278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy Folfirinox, 4 cycles
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50 Gy, 2 Gy/session; 25 fractions
Description: Radiochemotherapy 5 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50 Gy, 2 Gy/session; 25 fractions
Description: Radiochemotherapy 5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision in good responders
Description: If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local excision in good responders
Description: If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal excision in bad responders

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal excision in bad responders
Study: NCT03353753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCC-2618
Description: Oral KIT/PDGFRA kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT02704494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 500mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan
Description: Losartan 12.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 12.5mg daily
Study: NCT04626193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
Study: NCT02540096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training and Relaxation
Description: Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
Study: NCT03721393

Intervention type: DEVICE
Intervention: Wearable heart monitor
Description: Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.

Intervention type: DEVICE
Intervention: Wearable heart monitor
Description: Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
Study: NCT04413643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation
Description: The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
Study: NCT06563856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEPEZZA
Description: Administered as a SubQ injection or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEPEZZA
Description: Administered as a SubQ injection or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEPEZZA
Description: Administered as a SubQ injection or IV injection.
Study: NCT03839017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAXMARCHERYAN2
Description: Digital cognitive aid during the management of simulated war wounded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAXMARCHERYAN2
Description: Digital cognitive aid during the management of simulated war wounded.
Study: NCT01000779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: upto 320mg/day maximum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multi band ligator for esophageal varices
Description: to obliterate esophageal varices
Study: NCT00748085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation
Description: Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
Study: NCT00245414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 48 weeks
Study: NCT02514278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1600 mg/m2 daily 5 days/7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1600 mg/m2 daily 5 days/7
Study: NCT01480505

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy with gas tamponade
Description: A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment.
Study: NCT06563856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEPEZZA
Description: Administered as a SubQ injection or IV injection.
Study: NCT00245414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: 180μg for s.c./week for 24 weeks
Study: NCT05194046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg 1capsule
Description: will be orally administered
Study: NCT06563856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP
Description: Administered as a SubQ injection.
Study: NCT03405740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Management
Description: 1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access
Study: NCT04205968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT03525171

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic hyperinsulinemic clamp
Description: In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: euglycemic hyperinsulinemic clamp
Description: In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
Study: NCT01550731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE website
Description: Advance care planning website and materials plus an advance directive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance directive
Description: The control group will only receive an advance directive.
Study: NCT05581862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 meals+3 snacks
Description: All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 meals
Description: All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
Study: NCT02438020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One tablet of 500 mg will be ingested before the main meal
Study: NCT05652244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implants
Description: En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
Study: NCT02438020

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet will be ingested daily before main meal.
Study: NCT03461913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Lower segment elective Cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Lower segment elective Cesarean section
Study: NCT05652244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpalatal arche (TPA)
Description: Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.